270 related articles for article (PubMed ID: 21485696)
41. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.
LLerena A; Naranjo ME; Rodrigues-Soares F; Penas-LLedó EM; Fariñas H; Tarazona-Santos E
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1569-83. PubMed ID: 25316321
[TBL] [Abstract][Full Text] [Related]
42. Analysis of CYP2D6 genotype and response to tetrabenazine.
Mehanna R; Hunter C; Davidson A; Jimenez-Shahed J; Jankovic J
Mov Disord; 2013 Feb; 28(2):210-5. PubMed ID: 23280482
[TBL] [Abstract][Full Text] [Related]
43. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).
Berm EJ; Hak E; Postma M; Boshuisen M; Breuning L; Brouwers JR; Dhondt T; Jansen PA; Kok RM; Maring JG; van Marum R; Mulder H; Voshaar RC; Risselada AJ; Venema H; Vleugel L; Wilffert B
Trials; 2015 Jan; 16():37. PubMed ID: 25636328
[TBL] [Abstract][Full Text] [Related]
44. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases.
Zackrisson AL; Lindblom B; Ahlner J
Clin Pharmacol Ther; 2010 Sep; 88(3):354-9. PubMed ID: 19907421
[TBL] [Abstract][Full Text] [Related]
45. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.
Cacabelos R; Llovo R; Fraile C; Fernández-Novoa L
Curr Alzheimer Res; 2007 Sep; 4(4):479-500. PubMed ID: 17908053
[TBL] [Abstract][Full Text] [Related]
46. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication.
Steijns LS; Van Der Weide J
Clin Chem; 1998 May; 44(5):914-7. PubMed ID: 9590361
[TBL] [Abstract][Full Text] [Related]
47. Pharmacogenetics of classical and new antipsychotic drugs.
Otani K; Aoshima T
Ther Drug Monit; 2000 Feb; 22(1):118-21. PubMed ID: 10688273
[TBL] [Abstract][Full Text] [Related]
48. Accurate determination of the CYP2D6 (*1/*4)xN genotype by quantitative PCR.
Pondman KM; van Schaik RHN; van der Weide J
Drug Metab Pers Ther; 2018 Mar; 33(1):33-39. PubMed ID: 29420304
[TBL] [Abstract][Full Text] [Related]
49. Results and challenges of Cytochrome P450 2D6 (CYP2D6) testing in an ethnically diverse South Florida population.
Salyakina D; Roy S; Wang W; Oliva M; Akhouri R; Sotto I; Mulas N; Solano R; Fernández JR; Sanchez S; Shamshad U; Perlyn C; McCafferty-Fernandez J
Mol Genet Genomic Med; 2019 Sep; 7(9):e922. PubMed ID: 31389673
[TBL] [Abstract][Full Text] [Related]
50. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes.
Lundqvist E; Johansson I; Ingelman-Sundberg M
Gene; 1999 Jan; 226(2):327-38. PubMed ID: 9931507
[TBL] [Abstract][Full Text] [Related]
51. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.
Hicks JK; Swen JJ; Gaedigk A
Curr Drug Metab; 2014 Feb; 15(2):218-32. PubMed ID: 24524666
[TBL] [Abstract][Full Text] [Related]
52. Detection and characterization of the CYP2D6*9x2 gene duplication in two Spanish populations: resolution of AmpliChip CYP450 test no-calls.
Gaedigk A; Hernandez J; García-Solaesa V; Sánchez S; Isidoro-García M
Pharmacogenomics; 2011 Nov; 12(11):1617-22. PubMed ID: 22044417
[TBL] [Abstract][Full Text] [Related]
53. CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction.
Gaedigk A; Fuhr U; Johnson C; Bérard LA; Bradford D; Leeder JS
Pharmacogenomics; 2010 Jan; 11(1):43-53. PubMed ID: 20017671
[TBL] [Abstract][Full Text] [Related]
54. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
55. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?
Herbild L; Andersen SE; Werge T; Rasmussen HB; Jürgens G
Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):266-72. PubMed ID: 23731498
[TBL] [Abstract][Full Text] [Related]
56. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.
Thuerauf N; Lunkenheimer J
Eur Arch Psychiatry Clin Neurosci; 2006 Aug; 256(5):287-93. PubMed ID: 16783493
[TBL] [Abstract][Full Text] [Related]
57. Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.
Dorado P; González I; Naranjo ME; de Andrés F; Peñas-Lledó EM; Calzadilla LR; LLerena A
OMICS; 2017 Jan; 21(1):17-26. PubMed ID: 28271978
[TBL] [Abstract][Full Text] [Related]
58. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.
Linder MW; Prough RA; Valdes R
Clin Chem; 1997 Feb; 43(2):254-66. PubMed ID: 9023127
[TBL] [Abstract][Full Text] [Related]
59. Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication.
Ledesma MC; Agúndez JA
Clin Chem; 2005 Jun; 51(6):939-43. PubMed ID: 15817819
[TBL] [Abstract][Full Text] [Related]
60. Pharmacogenetics of antidepressants: clinical aspects.
Bertilsson L; Dahl ML; Tybring G
Acta Psychiatr Scand Suppl; 1997; 391():14-21. PubMed ID: 9265947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
